Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21911083 | 0.92 | NTRK1 (0.54) | NTRK1JAK2 | |
| SCHEMBL23732307 | 0.92 | NTRK1 (0.54) | NTRK1JAK2 | |
| SCHEMBL23149413 | 0.89 | NTRK1 (0.70) | NTRK1JAK2 | |
| SCHEMBL21911081 | 0.89 | NTRK1 (0.55) | NTRK1JAK2 | |
| SCHEMBL21911085 | 0.86 | NTRK1 (0.70) | NTRK1JAK2 | |
| SCHEMBL23317826 | 0.84 | NTRK1 (0.48) | NTRK1JAK2 | |
| SCHEMBL22849675 | 0.84 | NTRK1 (0.48) | NTRK1JAK2 | |
| SCHEMBL24168768 | 0.81 | NTRK1 (0.51) | NTRK1JAK2 | |
| SCHEMBL24030442 | 0.80 | NTRK1 (0.65) | NTRK1JAK2 | |
| SCHEMBL2599268 | 0.80 | NTRK1 (0.70) | NTRK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210403485-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE AS SELECTIVE TRK INHIBITOR | SHANDONG LUYE PHARMACEUTICAL CO., LTD. (CN) | 2021-12-30 | — | — | US | disclosed |
| EP-3858834-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE AS SELECTIVE TRK INHIBITOR | Shandong Luye Pharmaceutical Co., Ltd. (CN) | 2021-08-04 | — | — | EP | disclosed |
| WO-2020063965-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE AS SELECTIVE TRK INHIBITOR | 南京明德新药研发有限公司 | 2020-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403485-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE AS SELECTIVE TRK INHIBITOR | NTRK1, RET, TTK | NTRK1 1/4885JAK2 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.